March 28, 2014

Neuronetics, Inc.
c/o Judy P. Ways, Ph.D.
Vice President, Regulatory Affairs and Quality Assurance
31 General Warren Boulevard
Malvern, PA 19355

Re: K133408
Trade/Device Name: NeuroStar TMS Therapy System
Regulation Number: 21 CFR 882.5805
Regulation Name: Repetitive Transcranial Magnetic Stimulation System
Regulatory Class: Class II
Product Code: OBP
Dated: February 26, 2014
Received: February 27, 2014

Dear Dr. Ways:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA’s issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act’s requirements, including, but not limited to: registration and listing (21
CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical
device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set
forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic
product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please
contact the Division of Small Manufacturers, International and Consumer Assistance at its toll-
free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note
the regulation entitled, “Misbranding by reference to premarket notification” (21 CFR Part
807.97). For questions regarding the reporting of adverse events under the MDR regulation (21
CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH’s Office
of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the
Division of Small Manufacturers, International and Consumer Assistance at its toll-free number
(800) 638-2041 or (301) 796-7100 or at its Internet address

Sincerely yours,

Carlos L. Peña-S

Carlos L. Peña, PhD, MS
Director
Division of Neurological and
Physical Medicine Devices
Office of Device Evaluation
Center for Devices and Radiological Health

Enclosure
<table>
<thead>
<tr>
<th>Indications for Use</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>510(k) Number (if known)</strong></td>
</tr>
<tr>
<td>K133408</td>
</tr>
<tr>
<td><strong>Device Name</strong></td>
</tr>
<tr>
<td>NeuroStar TMS Therapy System</td>
</tr>
<tr>
<td><strong>Indications for Use (Describe)</strong></td>
</tr>
<tr>
<td>The NeuroStar TMS Therapy System is indicated for the treatment of Major Depressive Disorder in adult patients who have failed to receive satisfactory improvement from prior antidepressant medication in the current episode.</td>
</tr>
</tbody>
</table>

**Type of Use (Select one or both, as applicable)**

- [x] Prescription Use (Part 21 CFR 801 Subpart D)
- [ ] Over-The-Counter Use (21 CFR 801 Subpart C)

**FOR FDA USE ONLY**

Concurrence of Center for Devices and Radiological Health (CDRH) (Signature)

Carlos L. Pena -S
This section applies only to requirements of the Paperwork Reduction Act of 1995.

"DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW."

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services
Food and Drug Administration
Office of Chief Information Officer
Paperwork Reduction Act (PRA) Staff
PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
Neuronetics, Inc.
c/o Judy P. Ways, Ph.D.
Vice President, Regulatory Affairs and Quality Assurance
31 General Warren Boulevard
Malvern, PA 19355

Re: K130233
  NeuroStar TMS Therapy System
  Regulation Number: 21 CFR 882.5805
  Regulation Name: Repetitive Transcranial Magnetic Stimulator for Treatment of Major
                  Depressive Disorder
  Regulatory Class: Class II
  Product Code: OBP
  Dated: January 29, 2013
  Received: January 30, 2013

Dear Dr. Ways:

We have reviewed your Section 510(k) premarket notification of intent to market the device
referred above and have determined the device is substantially equivalent (for the indications
for use stated in the enclosure) to legally marketed predicate devices marketed in interstate
commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to
devices that have been reclassified in accordance with the provisions of the Federal Food, Drug,
and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA).
You may, therefore, market the device, subject to the general controls provisions of the Act. The
general controls provisions of the Act include requirements for annual registration, listing of
devices, good manufacturing practice, labeling, and prohibitions against misbranding and
adulteration. Please note: CDRH does not evaluate information related to contract liability
warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA),
it may be subject to additional controls. Existing major regulations affecting your device can be
found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may
publish further announcements concerning your device in the Federal Register.

Please be advised that FDA’s issuance of a substantial equivalence determination does not mean
that FDA has made a determination that your device complies with other requirements of the Act
or any Federal statutes and regulations administered by other Federal agencies. You must
comply with all the Act’s requirements, including, but not limited to: registration and listing (21
CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical
device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set
forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 331-342 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address: http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to: http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH’s Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address: http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

Joyce D. Wang -S

for Victor Krauthamer, Ph.D.
Acting Director
Division of Neurological and Physical Medicine Devices
Office of Device Evaluation
Center for Devices and Radiological Health

Enclosure
Indications for Use

510(k) Number: K130233

Device Name: NeuroStar TMS Therapy System

Indications For Use:

The NeuroStar TMS Therapy System is indicated for the treatment of Major Depressive Disorder in adult patients who have failed to achieve satisfactory improvement from one prior antidepressant medication at or above the minimal effective dose and duration in the current episode.

Prescription Use _X___ AND/OR Over-The-Counter Use _____
(Part 21 CFR 801 Subpart D) (21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Joyce Hwang -S
(Division Sign Off)
Division of Neurological and Physical Medicine Devices (DNPMED)

510(k) Number _K130233________
Neuronetics, Inc.
c/o Judy P. Ways, Ph.D.
Vice President, Regulatory Affairs and Quality Assurance
One Great Valley Parkway, Suite 2
Malvern, PA 19355

Re: K061053; NeuroStar® TMS System
   Evaluation of Automatic Class III Designation
   Regulation Number: 21 CFR 882.5805
   Classification: II
   Product Code: OBP

Dear Dr. Ways:

This letter corrects our classification letter of October 7, 2008.

The Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) has completed its review of your Evaluation of Automatic Class III Designation Petition (de novo) for classification of the NeuroStar® TMS System as a prescription device under 21 CFR Part 801.109 that is indicated for the treatment of Major Depressive Disorder in adult patients who have failed to achieve satisfactory improvement from one prior antidepressant medication at or above the minimal effective dose and duration in the current episode. FDA concludes that this device, and substantially equivalent devices of this generic type, should be classified into class II. This order, therefore, classifies the NeuroStar® TMS System, and substantially equivalent devices of this generic type into class II under the generic name, Repetitive Transcranial Magnetic Stimulation (rTMS) System.

FDA identifies this generic type of device as:

A repetitive transcranial magnetic stimulation (rTMS) system is an external device that delivers transcranial repetitive pulsed magnetic fields of sufficient magnitude to induce neural action potentials in the prefrontal cortex to treat the symptoms of major depressive disorder (MDD) without inducing seizure in patients who have failed at least one antidepressant medication and are currently not on any antidepressant therapy.
In accordance with section 513(f)(1) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360(f)(1)) (the act), devices that were not in commercial distribution prior to May 28, 1976 (the date of enactment of the Medical Device Amendments of 1976 (the amendments)), generally referred to as postamendments devices, are classified automatically by statute into class III without any FDA rulemaking process. These devices remain in class III and require premarket approval, unless and until the device is classified or reclassified into class I or II or FDA issues an order finding the device to be substantially equivalent, in accordance with section 513(i) of the act (21 U.S.C. 360c(i)), to a predicate device that does not require premarket approval. The agency determines whether new devices are substantially equivalent to previously marketed devices by means of premarket notification procedures in section 510(k) of the act (21 U.S.C. 360(k)) and Part 807 of the FDA regulations (21 CFR 807).

Section 513(f)(2) of the act provides that any person who submits a premarket notification under section 510(k) for a device may, with in 30 days after receiving an order classifying the device in class III under section 513(f)(1), request FDA to classify the device under the criteria set forth in section 513(a)(1). FDA shall, within 60 days of receiving such a request classify the device. This classification shall be the initial classification of the device. Within 30 days after the issuance of an order classifying the device, FDA must publish a notice in the Federal Register classifying the device type.

On May 24, 2007, FDA filed your petition requesting classification of the NeuroStar® TMS System into class II. The petition was submitted under section 513(f)(2) of the act. In accordance with section 513(f)(1) of the act, FDA issued an order on April 26, 2007 automatically classifying the NeuroStar® TMS System in class III, because it was not within a type of device which was introduced or delivered for introduction into interstate commerce for commercial distribution before May 28, 1976, nor which was subsequently reclassified into class I or class II. To classify the NeuroStar® TMS System into class I or II, it is necessary that the proposed class has sufficient regulatory controls to provide reasonable assurance of the safety and effectiveness of the device for its intended use.

After review of the information submitted in the petition, FDA has determined that the NeuroStar® TMS System indicated for the treatment of Major Depressive Disorder in adult patients who have failed to achieve satisfactory improvement from one prior antidepressant medication at or above the minimal effective dose and duration in the current episode can be classified in class II with the establishment of special controls for class II. FDA believes that class II special controls provide reasonable assurance of the safety and effectiveness of the device type.
Risks involved with the use of the device and their mitigation include:

<table>
<thead>
<tr>
<th>Identified Risk</th>
<th>Mitigation Measures</th>
</tr>
</thead>
<tbody>
<tr>
<td>Usage outside of labeled patient population</td>
<td>Clinical Testing</td>
</tr>
<tr>
<td></td>
<td>Labeling</td>
</tr>
<tr>
<td>Ineffective Treatment</td>
<td>Nonclinical Analysis and Testing</td>
</tr>
<tr>
<td></td>
<td>Software Life Cycle and Risk Management</td>
</tr>
<tr>
<td></td>
<td>Animal Testing</td>
</tr>
<tr>
<td></td>
<td>Clinical Testing</td>
</tr>
<tr>
<td></td>
<td>Labeling</td>
</tr>
<tr>
<td>Seizure</td>
<td>Nonclinical Analysis and Testing</td>
</tr>
<tr>
<td></td>
<td>Animal Testing</td>
</tr>
<tr>
<td></td>
<td>Clinical Testing</td>
</tr>
<tr>
<td></td>
<td>Labeling</td>
</tr>
<tr>
<td>Scalp discomfort, scalp burn, or other adverse effects</td>
<td>Nonclinical Analysis and Testing</td>
</tr>
<tr>
<td></td>
<td>Software Life Cycle and Risk Management</td>
</tr>
<tr>
<td></td>
<td>Animal Testing</td>
</tr>
<tr>
<td></td>
<td>Clinical Testing</td>
</tr>
<tr>
<td></td>
<td>Labeling</td>
</tr>
<tr>
<td>Magnetic field effects on functioning of other</td>
<td>Non-clinical Analysis and Testing</td>
</tr>
<tr>
<td>medical devices</td>
<td>Labeling</td>
</tr>
<tr>
<td>Adverse Tissue Reaction</td>
<td>Biocompatibility</td>
</tr>
<tr>
<td>Hazards Associated with Electrical Equipment</td>
<td>Electrical Equipment Safety</td>
</tr>
<tr>
<td></td>
<td>Labeling</td>
</tr>
<tr>
<td>Hazards caused by Electromagnetic Interference and</td>
<td>Electromagnetic Compatibility</td>
</tr>
<tr>
<td>Electrostatic Discharge Hazards</td>
<td>Labeling</td>
</tr>
<tr>
<td>Hearing Loss</td>
<td>Labeling</td>
</tr>
</tbody>
</table>

In addition to the general controls of the act, the NeuroStar® TMS System is subject to the following categories of special controls: device description, nonclinical analysis and testing, biocompatibility, electrical equipment safety, electromagnetic compatibility, wireless technology, software validation, clinical information and labeling. Section 510(m) of the act provides that FDA may exempt a class II device from the premarket notification requirements under section 510(k) of the act, if FDA determines that premarket notification is not necessary to provide reasonable assurance of the safety and effectiveness of the device type. FDA has determined premarket notification is necessary to provide reasonable assurance of the safety and effectiveness of the device type and, therefore, the device is not exempt from the premarket notification requirements of the act. Thus, persons who intend to market this device type must submit to FDA a premarket notification submission containing information on the rTMS system they intend to market prior to marketing the device and receive clearance to market from FDA.
A notice announcing this classification order will be published in the Federal Register. A copy of this order and supporting documentation are on file in the Dockets Management Branch (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Room 1061, Rockville, MD 20852 and are available for inspection between 9 a.m. and 4 p.m., Monday through Friday.

As a result of this order, you may immediately market your device as described in the de novo, subject to the general control provisions of the act and the special controls identified in this order.

If you have any questions concerning this classification order, please contact Ann H. Costello Ph.D., D.M.D. at 301-776-6493.

Sincerely yours,

Jonette Foy, Ph.D.
Acting Deputy Director
for Science and Regulatory Policy
Office of Device Evaluation
Center for Devices and
Radiological Health
Dear Dr. Ways,

The Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) has completed its review of your petition for classification of the NeuroStar® TMS System as a prescription device under 21 CFR Part 801.109 that is indicated for the treatment of Major Depressive Disorder in adult patients who have failed to achieve satisfactory improvement from one prior antidepressant medication at or above the minimal effective dose and duration in the current episode. FDA concludes that this device, and substantially equivalent devices of this generic type, should be classified into class II. This order, therefore, classifies the NeuroStar® TMS System, and substantially equivalent devices of this generic type into class II under the generic name, Transcranial magnetic stimulation system. This order also identifies the special controls applicable to this device if put into class II.

FDA identifies this generic type of device as:

21 CFR 882.5805. A transcranial magnetic stimulation system is a device intended for the treatment of major depressive disorder (MDD) that non-invasively delivers repetitive pulsed magnetic fields of sufficient magnitude to induce neural action potentials in the patient’s cerebral cortex to treat the symptoms of MDD without inducing seizure.
In accordance with section 513(f)(1) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360c(f)(1)) (the act), devices that were not in commercial distribution prior to May 28, 1976 (the date of enactment of the Medical Device Amendments of 1976 (the amendments)), generally referred to as postamendments devices, are classified automatically by statute into class III without any FDA rulemaking process. These devices remain in class III and require premarket approval, unless and until the device is classified or reclassified into class I or II or FDA issues an order finding the device to be substantially equivalent, in accordance with section 513(i) of the act (21 U.S.C. 360c(i)), to a predicate device that does not require premarket approval. The agency determines whether new devices are substantially equivalent to previously marketed devices by means of premarket notification procedures in section 510(k) of the act (21 U.S.C. 360(k)) and Part 807 of the FDA regulations (21 CFR 807).

Section 513(f)(2) of the act provides that any person who submits a premarket notification under section 510(k) for a device may, with in 30 days after receiving an order classifying the device in class III under section 513(f)(1), request FDA to classify the device under the criteria set forth in section 513(a)(1). FDA shall, within 60 days of receiving such a request classify the device. This classification shall be the initial classification of the device. Within 30 days after the issuance of an order classifying the device, FDA must publish a notice in the Federal Register classifying the device.

On May 24, 2007, FDA filed your petition requesting classification of the NeuroStar® TMS System into class II. The petition was submitted under section 513(f)(2) of the act. In accordance with section 513(f)(1) of the act, FDA issued an order on April 26, 2007 automatically classifying the NeuroStar® TMS System in class III, because it was not within a type of device which was introduced or delivered for introduction into interstate commerce for commercial distribution before May 28, 1976, which was subsequently reclassified into class I or class II. In order to classify the NeuroStar® TMS System into class I or II, it is necessary that the proposed class have sufficient regulatory controls to provide reasonable assurance of the safety and effectiveness of the device for its intended use.

After review of the information submitted in the petition, FDA has determined that the NeuroStar® TMS System indicated for the treatment of Major Depressive Disorder in adult patients who have failed to achieve satisfactory improvement from one prior antidepressant medication at or above the minimal effective dose and duration in the current episode can be classified in class II with the establishment of special controls. FDA believes that class II special controls provide reasonable assurance of the safety and effectiveness of the device type.

Risks involved with the use of the device type and their mitigation include:
<table>
<thead>
<tr>
<th>Identified Risk</th>
<th>Mitigation Measures</th>
</tr>
</thead>
<tbody>
<tr>
<td>Usage outside of labeled patient population</td>
<td>Clinical Testing</td>
</tr>
<tr>
<td></td>
<td>Labeling</td>
</tr>
<tr>
<td>Ineffective Treatment</td>
<td>Nonclinical Analysis and Testing</td>
</tr>
<tr>
<td></td>
<td>Software Life Cycle and Risk Management</td>
</tr>
<tr>
<td></td>
<td>Animal Testing</td>
</tr>
<tr>
<td></td>
<td>Clinical Testing</td>
</tr>
<tr>
<td></td>
<td>Labeling</td>
</tr>
<tr>
<td>Seizure</td>
<td>Nonclinical Analysis and Testing</td>
</tr>
<tr>
<td></td>
<td>Animal Testing</td>
</tr>
<tr>
<td></td>
<td>Clinical Testing</td>
</tr>
<tr>
<td></td>
<td>Labeling</td>
</tr>
<tr>
<td>Scalp discomfort, scalp burn, or other adverse effects</td>
<td>Nonclinical Analysis and Testing</td>
</tr>
<tr>
<td></td>
<td>Software Life Cycle and Risk Management</td>
</tr>
<tr>
<td></td>
<td>Animal Testing</td>
</tr>
<tr>
<td></td>
<td>Clinical Testing</td>
</tr>
<tr>
<td></td>
<td>Labeling</td>
</tr>
<tr>
<td>Magnetic field effects on functioning of other medical devices</td>
<td>Non-clinical Analysis and Testing</td>
</tr>
<tr>
<td></td>
<td>Labeling</td>
</tr>
<tr>
<td>Adverse Tissue Reaction</td>
<td>Biocompatibility</td>
</tr>
<tr>
<td>Hazards Associated with Electrical Equipment</td>
<td>Electrical Equipment Safety</td>
</tr>
<tr>
<td></td>
<td>Labeling</td>
</tr>
<tr>
<td>Hazards caused by Electromagnetic Interference and Electrostatic Discharge Hazards</td>
<td>Electromagnetic Compatibility</td>
</tr>
<tr>
<td></td>
<td>Labeling</td>
</tr>
<tr>
<td>Hearing Loss</td>
<td></td>
</tr>
</tbody>
</table>

In addition to the general controls of the act, the transcranial magnetic stimulation system for the treatment of major depressive disorder is subject to the following special controls: device description, nonclinical analysis and testing, biocompatibility, electrical equipment safety, electromagnetic compatibility, wireless technology, software validation, clinical information and labeling. Section 510(m) of the act provides that FDA may exempt a class II device from the premarket notification requirements under section 510(k) of the act, if FDA determines that premarket notification is not necessary to provide reasonable assurance of the safety and effectiveness of the device. FDA has determined premarket notification is necessary to provide reasonable assurance of the safety and effectiveness of the device type and, therefore, the device is not exempt from the premarket notification requirements. Thus, persons who intend to market this device must submit to FDA a premarket notification submission containing information on the transcranial magnetic...
stimulation system they intend to market prior to marketing the device and receive clearance to market from FDA.

A notice announcing this classification order will be published in the Federal Register. A copy of this order and supporting documentation are on file in the Dockets Management Branch (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Room 1061, Rockville, MD 20852 and are available for inspection between 9 a.m. and 4 p.m., Monday through Friday.

As a result of this order, you may immediately market this device, subject to the general control provisions of the act and the special controls identified in this order.

If you have any questions concerning this classification order, please contact Ann H. Costello, Ph.D., D.M.D. at (240) 276-3740.

Sincerely yours,

Donna-Bea Tillman, Ph.D., M.P.A.
Director
Office of Device Evaluation
Center for Devices and Radiological Health